Iimvavanyo zokubopha iprotein ye-Spike kunye novavanyo lokungathathi hlangothi kusetyenziswa iintsholongwane ezimele zonke ii-SARS-CoV-2 ezahlukeneyo ezixhalabisayo (VOCs) zigqitywe nge-STI-9167, kwaye le nAb yabonwa ukuba ibophelela ngokusondelelana okuphezulu kunye nokubonelela ngomsebenzi onamandla kakhulu wokungathathi hlangothi (Omicron IC50 = 25 ng/ml). Ngokubaluleka okuphawulweyo, i-STI-9167 yahlukile xa ithelekiswa novavanyo lwe-EUA-evunyiweyo yi-SARS-CoV-2 nAbs apho iipropati zokubophelela kunye nokungathathi hlangothi zigcinwa ngokuchasene ne-Omicron esakhulayo kunye ne-Omicron (+R346K) eyahlukileyo, ukwahluka okukhulayo komnombo we-Omicron. ifaka i-R346K ukuguqulwa kweprotheyini yeSpike eyongezelelweyo. Ukongeza, i-STI-9167 elawulwa ngedosi ephantsi (5mg/kg) mhlawumbi nge-intranasal okanye iindlela zokungena emithanjeni zibonelele ngokhuseleko oluluqilima kwiimpawu zekliniki zosulelo ngokwahluka kwe-Omicron kwimodeli yempuku ye-K18-hAce2 ye-COVID-19, ukuthintela ubunzima. ilahleko kunye nokunciphisa titers zentsholongwane emiphungeni ukuya kumanqanaba angabonakaliyo.
"Isizukulwana kunye neempawu ze-STI-9167 nAb zibonisa intsebenziswano enkulu phakathi kwenzululwazi yeNtaba yeSinayi kunye neSorrento ukulungisa ingxaki yezempilo yehlabathi," watsho uDomenico Tortorella, PhD, uNjingalwazi weMicrobiology e-Icahn Mount Sinai.
“Sikhethe i-antibody STI-9167 kwiiseti ezinkulu ezahlukeneyo ze-anti-SARS-CoV-2 spike neutralizing antibodies esiziphuhlise kwiilebhu zethu. Ibonise eyona ndlela isebenzayo yokuwela ecaleni kwayo yonke i-SARS-CoV-2 eyaziwayo yodwa kunye nokwahluka kweenkxalabo, kubandakanya nokwahluka kwe-Omicron kunye ne-Omicron (+R346K) yamva nje,” utshilo u-J. Andrew Duty, PhD, uNjingalwazi oNcedisayo weMicrobiology kunye noMlawuli Iziko loPhuhliso loNyango lwe-Antibody kwi-Icahn Mount Sinai.
"Ii-nAbs ezivunyiweyo ngoku ze-EUA ziye zanciphisa ngokuphawulekayo okanye zingekhoyo kunye nezenzo zokuzibophelela kunye nokungathathi hlangothi ngokuchasene ne-omicron/omicron (+R346K) ibenza banganelanga ukuxhasa iimfuno zangoku zeklinikhi," utshilo uMike A. Royal, MD, JD, MBA, iGosa eliyiNtloko lezoNyango Sorrento. “Ezinye ii-nAbs zifuneka kakhulu kwixesha elikufuphi, ngakumbi kubantwana ababonakala besemngciphekweni omkhulu wosulelo lwe-omicron kunye nokulaliswa esibhedlele. Uqulunqo lwethu lwe-COVIDROPS lwangaphakathi luzisa ii-nAbs zethu kwiindlela zomoya eziphezulu apho i-Omicron idla ngokujolisa kwaye ichume, kwaye njengonyango olungaphazamisiyo, olulula ukulunika unyango, ilungele abantwana. Sele siqalisile ukunyanga abantwana abane-COVIDROPS (nge-STI-2099) eMexico apho ukwahluka kwe-delta kusaxhaphakile. Ngezifundo zeSigaba sesi-2 e-US, e-United Kingdom naseMexico, sibone iprofayile yokhuseleko ekhuselekileyo yokuhanjiswa kwangaphakathi kwee-nAbs zethu kwaye silindele iziphumo ezifanayo nge-COVIDROP (ene-STI-9167).
“Ngoku sinamava okuzisa unyango lwe-COVID-19 eklinikhi kwaye siqhubela phambili uninzi kwiSigaba sesi-2 kunye/okanye nophuhliso olubalulekileyo,” utshilo uMark Brunswick, PhD, SVP kunye neNtloko yeMicimbi yoLawulo kunye noMgangatho eSorrento. "Sikwimeko entle yokuzisa ngokukhawuleza i-COVISHIELD kwinqanaba le-IND naseklinikhi kwaye silindele ukufaka le IND ibalulekileyo kwinyanga ezayo."
UGqr. Henry Ji, uSihlalo kunye ne-CEO ye-Sorrento, uthe, "Umsebenzi wamaqela e-Sorrento kunye neNtaba yeSinayi uye wavelisa i-antibody ephawulekayo enezakhiwo ezizodwa kunye nexabiso elikhuselayo kwi-Omicron kunye nazo zonke ezinye ii-SARS-CoV-2 VOCs. I-COVISHIELD yethu yokungathathi hlangothi i-antibody yeyona ibalaseleyo kudidi kunye noyena mgqatswa uhambele phambili ekulweni i-Omicron exhaphakileyo kunye ne-Omicron ekhulayo (+R346K) VOCs. Sisebenza ngenkuthalo ukubeka le anti-anti ukuba isetyenziswe kwizigulana ze-COVID kwaye siqinisekile ukuba indlela yethu iya kubonelela ngesisombululo esisebenzayo sekliniki kungekuphela nje kwixesha elikufuphi kodwa nanjengoko ubhubhane uqhubeka nokuvela. ”
Umbhalo-ngqangi wangaphambili wangeniswa nge-19 kaJanuwari 2022 kwaye uya kupapashwa kungekudala kwi-intanethi kwi-biorxiv.org.
I-antibody engathathi hlangothi echaziweyo yenziwa kwiilabhoratri zeNtaba yeSinayi kwaye inikwe ilayisenisi yeSorrento Therapeutics. INtaba yeSinayi kunye namalungu e-faculty yeNtaba yeSinayi anomdla wemali kwi-Sorrento Therapeutics.
INTO ONOKUYITHATHA KWELI NQAKU:
- Additionally, STI-9167 administered at a low dose (5mg/kg) by either the intranasal or intravenous routes provided strong protection against the clinical signs of infection by the Omicron variant in the K18-hAce2 transgenic mouse model of COVID-19, preventing weight loss and reducing virus titers in the lungs to undetectable levels.
- Of noted significance, STI-9167 is unique when compared to tests of EUA-approved SARS-CoV-2 nAbs in that binding and neutralization properties are maintained against the emerging Omicron and Omicron (+R346K) variant, an increasingly prevalent Omicron lineage variant that encodes an additional R346K Spike protein mutation.
- Our intranasal COVIDROPS formulation delivers our nAbs to the upper airways where Omicron is most likely to target and flourish, and as a non-invasive, easy to administer treatment, it is ideal for children.
